Page 130 - 南京医科大学自然版

第45卷第1期
·124 · 南 京 医 科 大 学 学 报 2025年1月

Left ventricular systolic dysfunction in patients diagnosed ［20］TOLKATCHEV D，SMITH G E，KOSTYUKOVA A S.
with hypertrophic cardiomyopathy during childhood：in⁃ Role of intrinsic disorder in muscle sarcomeres［J］. Prog
sights from the SHaRe registry［J］. Circulation，2023，148 Mol Biol Transl Sci，2019，166：311-340
（5）：394-404 ［21］RISI C，BELKNAP B，FORGACS⁃LONART E，et al. N⁃
［8］ MARSTON N A，HAN L，OLIVOTTO I，et al. Clinical terminal domains of cardiac myosin binding protein C co⁃
characteristics and outcomes in childhood⁃onset hypertro⁃ operatively activate the thin filament［J］. Structure，2018，
phic cardiomyopathy［J］. Eur Heart J，2021，42（20）： 26（12）：1604-1611
1988-1996 ［22］BELKNAP B，HARRIS S P，WHITE H D. Modulation of
［9］ CHAN W X，YANG S W，WANG J，et al. Clinical charac⁃ thin filament activation of myosin ATP hydrolysis by N⁃
teristics and survival of children with hypertrophic cardio⁃ terminal domains of cardiac myosin binding protein⁃C［J］.
myopathy in China：a multicentre retrospective cohort Biochemistry，2014，53（42）：6717-6724
study［J］. EClinical Medicine，2022，49：101466 ［23］WALCOTT S，DOCKEN S，HARRIS S P. Effects of cardiac
［10］TUDURACHI B S，ZAVOI A，LEONTE A，et al. An up⁃ myosin binding protein⁃C on actin motility are explained
date on MYBPC3 gene mutation in hypertrophic cardiomy⁃ with a drag⁃activation⁃competition model［J］. Biophys J，
opathy［J］. Int J Mol Sci，2023，24（13）：10510 2015，108（1）：10-13
［11］SUAY⁃CORREDERA C，ALEGRE⁃CEBOLLADA J. The ［24］HERRERA⁃RODRÍGUEZ D L，TOTOMOCH⁃SERRA A，
mechanics of the heart：zooming in on hypertrophic cardio⁃ ROSAS⁃MADRIGAL S，et al. Genes frequently associated
myopathy and cMyBP⁃C［J］. FEBS Lett，2022，596（6）： with sudden death in primary hypertrophic cardiomyopa⁃
703-746 thy［J］. Arch Cardiol Mex，2020，90（1）：58-68
［12］LORENZINI M，NORRISH G，FIELD E，et al. Penetrance ［25］RIBEIRO M，JAGER J，FURTADO M，et al. Generation
of hypertrophic cardiomyopathy in sarcomere protein mu⁃ of induced pluripotent stem cells from an individual with
tation carriers［J］. J Am Coll Cardiol，2020，76（5）：550- early onset and severe hypertrophic cardiomyopathy
559 linked to MYBPC3：c. 772G>A mutation［J］. Hum Cell，
［13］YASUDA M，KOSHIDA S，SATO N，et al. Complete pri⁃ 2024，37（4）：1205-1214
mary structure of chicken cardiac C ⁃ protein（MyBP ⁃ C） ［26］CARRIER L. Targeting the population for gene therapy
and its expression in developing striated muscles［J］. J with MYBPC3［J］. J Mol Cell Cardiol，2021，150：101-
Mol Cell Cardiol，1995，27（10）：2275-2286 108
［14］HELING L W H J，GEEVES M A，KAD N M. MyBP⁃C： ［27］SUAY ⁃ CORREDERA C，PRICOLO M R，HERRERO ⁃
one protein to govern them all［J］. J Muscle Res Cell Mo⁃ GALÁN E，et al. Protein haploinsufficiency drivers identify
til，2020，41（1）：91-101 MYBPC3 variants that cause hypertrophic cardiomyopa⁃
［15］DOH C Y，SCHMIDT A V，CHINTHALAPUDI K，et al. thy［J］. J Biol Chem，2021，297（1）：100854
Bringing into focus the central domains C3⁃C6 of myosin ［28］TRIVEDI D V，ADHIKARI A S，SARKAR S S，et al.
binding protein C［J］. Front Physiol，2024，15：1370539 Hypertrophic cardiomyopathy and the myosin mesa：
［16］WOODHEAD J L，ZHAO F Q，CRAIG R，et al. Atomic viewing an old disease in a new light［J］. Biophys Rev，
model of a myosin filament in the relaxed state［J］. Na⁃ 2018，10（1）：27-48
ture，2005，436（7054）：1195-1199 ［29］MÉNDEZ I，FERNÁNDEZ A I，ESPINOSA M Á，et al.
［17］BAREFIELD D，SADAYAPPAN S. Phosphorylation and Founder mutation in myosin ⁃ binding protein C with an
function of cardiac myosin binding protein ⁃ C in health early onset and a high penetrance in males［J］. Open
and disease［J］. J Mol Cell Cardiol，2010，48（5）：866- Heart，2021，8（2）：e001789
875 ［30］GROVER S，LLOYD R，PERRY R，et al. Assessment of
［18］KANASSATEGA R S，BUNCH T A，LEPAK V C，et al. myocardial oxygenation，strain，and diastology in MYBPC3⁃
Human cardiac myosin⁃binding protein C phosphorylation related hypertrophic cardiomyopathy：a cardiovascular
⁃ and mutation⁃dependent structural dynamics monitored magnetic resonance and echocardiography study［J］. Eur
by time ⁃ resolved FRET［J］. J Mol Cell Cardiol，2022， Heart J Cardiovasc Imaging，2019，20（8）：932-938
166：116-126 ［31］WESSELS M W，HERKERT J C，FROHN⁃MULDER I M，
［19］ GOVADA L，CHAYEN N E. Crystallisation and charac⁃ et al. Compound heterozygous or homozygous truncating
terisation of muscle proteins：a mini⁃review［J］. J Muscle MYBPC3 mutations cause lethal cardiomyopathy with fea⁃
Res Cell Motil，2023，44（3）：209-215 tures of noncompaction and septal defects［J］. Eur J Hum